Advertisement
Advertisement
Climb Bio’s Budoprutug Study: A Promising Step Forward
PremiumCompany AnnouncementsClimb Bio’s Budoprutug Study: A Promising Step Forward
19d ago
Climb Bio appoints Adam Villa as SVP, technical operations
Premium
The Fly
Climb Bio appoints Adam Villa as SVP, technical operations
26d ago
Climb Bio Releases New Clinical Data on Budoprutug
Premium
Company Announcements
Climb Bio Releases New Clinical Data on Budoprutug
30d ago
Climb Bio Appoints New CFO Susan Altschuller
PremiumCompany AnnouncementsClimb Bio Appoints New CFO Susan Altschuller
2M ago
Climb Bio appoints Altschuller as Chief Financial Officer
Premium
The Fly
Climb Bio appoints Altschuller as Chief Financial Officer
2M ago
Climb Bio price target raised to $8 from $7 at BTIG
Premium
The Fly
Climb Bio price target raised to $8 from $7 at BTIG
2M ago
Climb Bio initiated with an Outperform at Baird on budoprutug potential
PremiumThe FlyClimb Bio initiated with an Outperform at Baird on budoprutug potential
3M ago
Climb Bio initiated with an Outperform at Baird
Premium
The Fly
Climb Bio initiated with an Outperform at Baird
3M ago
Climb Bio Reports Progress in Clinical Trials and Financial Stability
Premium
Company Announcements
Climb Bio Reports Progress in Clinical Trials and Financial Stability
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100